Ftse Mib
34.395,62
0,06%
DAX
18.518,03
-0,44%
S&P 500
5.667,20
0,64%
NASDAQ
18.509,34
0,20%
Bitcoin
64.417,09
-0,67%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Blueprint Medicines Corporation (BPMC) Blueprint Medicines Corporation (BPMC) Notizie

BPMC

Blueprint Medicines (BPMC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BPMC
DataOraFonteTitoloSimboloCompagnia
06/06/202015:00PR Newswire (US)Blueprint Medicines Presents Updated Part 1 Data from PIONEER Trial of Avapritinib Showing Robust Reductions in Cutaneous Dis...NASDAQ:BPMCBlueprint Medicines Corporation
04/06/202022:38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BPMCBlueprint Medicines Corporation
03/06/202014:00PR Newswire (US)Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:BPMCBlueprint Medicines Corporation
29/05/202014:22Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BPMCBlueprint Medicines Corporation
29/05/202014:00PR Newswire (US)Blueprint Medicines Announces Data Presentations at ASCO20 Highlighting Deep, Durable Clinical Activity and Well-Tolerated Sa...NASDAQ:BPMCBlueprint Medicines Corporation
27/05/202022:30PR Newswire (US)Blueprint Medicines to Present at Upcoming Investors ConferencesNASDAQ:BPMCBlueprint Medicines Corporation
26/05/202014:00PR Newswire (US)Blueprint Medicines to Host Conference Call to Review Updated Clinical Data for Pralsetinib in RET-Altered Cancers on Friday,...NASDAQ:BPMCBlueprint Medicines Corporation
15/05/202014:00PR Newswire (US)Blueprint Medicines Receives Complete Response Letter from FDA for Avapritinib New Drug Application for the Treatment of Four...NASDAQ:BPMCBlueprint Medicines Corporation
14/05/202015:00PR Newswire (US)Blueprint Medicines Announces Data Presentations Highlighting Significant Progress in Advancing RET-Altered Cancer and System...NASDAQ:BPMCBlueprint Medicines Corporation
12/05/202018:42Edgar (US Regulatory)Sec Staff Action/letter (sec Staff)NASDAQ:BPMCBlueprint Medicines Corporation
06/05/202022:31Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:BPMCBlueprint Medicines Corporation
06/05/202015:19Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BPMCBlueprint Medicines Corporation
06/05/202013:00PR Newswire (US)Blueprint Medicines Reports First Quarter 2020 Financial ResultsNASDAQ:BPMCBlueprint Medicines Corporation
29/04/202022:26Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:BPMCBlueprint Medicines Corporation
29/04/202022:15Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:BPMCBlueprint Medicines Corporation
29/04/202014:00PR Newswire (US)Blueprint Medicines to Report First Quarter 2020 Financial Results on Wednesday, May 6, 2020NASDAQ:BPMCBlueprint Medicines Corporation
28/04/202013:00PR Newswire (US)Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with ...NASDAQ:BPMCBlueprint Medicines Corporation
10/04/202020:01Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:BPMCBlueprint Medicines Corporation
01/04/202014:00PR Newswire (US)Blueprint Medicines Announces the Achievement of Key Portfolio MilestonesNASDAQ:BPMCBlueprint Medicines Corporation
17/03/202022:11Edgar (US Regulatory)Unknown (sec Staff)NASDAQ:BPMCBlueprint Medicines Corporation
16/03/202018:44Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:BPMCBlueprint Medicines Corporation
16/03/202012:00PR Newswire (US)Blueprint Medicines Announces Part 1 Results from PIONEER Trial Showing Broad Activity of Avapritinib Across Measures of Mast...NASDAQ:BPMCBlueprint Medicines Corporation
09/03/202014:00PR Newswire (US)Blueprint Medicines to Report Updated Data from the Phase 2 PIONEER Trial of Avapritinib in Indolent Systemic Mastocytosis on...NASDAQ:BPMCBlueprint Medicines Corporation
24/02/202022:05PR Newswire (US)Blueprint Medicines to Present Updated Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mast...NASDAQ:BPMCBlueprint Medicines Corporation
19/02/202014:00PR Newswire (US)Blueprint Medicines to Present at Upcoming Investor ConferencesNASDAQ:BPMCBlueprint Medicines Corporation
18/02/202022:56Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:BPMCBlueprint Medicines Corporation
13/02/202023:33Edgar (US Regulatory)Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)NASDAQ:BPMCBlueprint Medicines Corporation
13/02/202022:41Edgar (US Regulatory)Annual Report (10-k)NASDAQ:BPMCBlueprint Medicines Corporation
13/02/202013:00PR Newswire (US)Blueprint Medicines Reports Fourth Quarter and Full Year 2019 Financial ResultsNASDAQ:BPMCBlueprint Medicines Corporation
06/02/202022:05PR Newswire (US)Blueprint Medicines to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 13, 2020NASDAQ:BPMCBlueprint Medicines Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BPMC

La tua Cronologia

LSE
CACX
Lyxor Cac40
NASDAQ
ESSA
ESSA Bancorp
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network